Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)

November 2013
National Guideline Clearinghouse;11/4/2013, p1
No abstract available.


Related Articles

  • Haemophilia.  // Independent Nurse;4/7/2008, p27 

    The article focuses on the cause, diagnosis, and treatment of haemophilia. It stated that severe forms of the said disease are characterised by bleeding into joints and major muscle groups. Haemophilia a A and B are indistinguishable and characterised by frequent spontaneous haemarthoses and...

  • Factor VIII/octocog-α: Factor VIII inhibitor development: case report.  // Reactions Weekly;Nov2013, Issue 1477, p17 

    The article presents a case study of a man with congenital haemophilia A who was treated with plasma-derived factor VIII or octocog-α (recombinant factor VIII) and developed factor VIII inhibitor.

  • Immunology: Oral solutions. Dolgin, Elie // Nature;11/27/2014 Supplement, Vol. 515 Issue s7528, pS166 

    The article focusses on treatment for haemophilia using bio-engineered oral pills from lettuce leaves to prevent inhibitor formation. Research by researchers Henry Daniell at the University Of Pennsylvania, Philadelphia, and David Lillicrap, of Queen's University in Kingston, Ontario, Canada,...

  • REKOMBINOWANY AKTYWNY CZYNNIK VII (rVIIa) -- WŁAÅšCIWOÅšCI FARMAKOLOGICZNE I ZASTOSOWANIE KLINICZNE. Zubkowicz, Marta; Chojnowski, Krzysztof // Problemy Terapii Monitorowanej;dec2007, Vol. 18 Issue 4, p245 

    Recombinant activated factor VII (rFVIIa; NovoSeven, NovoNordisk, Dennmark) was originally developed for the treatment of patients with haemophilia A and haemophilia B with inhibitory antibodies against factor VIII or factor IX. It has been approved in Europe for the treatment of haemorrhage in...

  • Diagnosis and management of haemophilia. Fijnvandraat, Karin; Cnossen, Marjon H.; Leebeek, Frank W. G.; Peters, Marjolein // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/5/2012, Vol. 344 Issue 7855, p36 

    The article discusses the current recommendations for the diagnosis and management of haemophilia, a hereditary disorder of haemostasis associated with prolonged and excessive bleeding. Basic knowledge of the inheritance and management of haemophilia is essential for healthcare workers, because...

  • Current Options and New Developments in the Treatment of Haemophilia. Wong, Trisha; Recht, Michael // Drugs;2011, Vol. 71 Issue 3, p305 

    Haemophilia A and B are X-linked bleeding disorders due to the inherited deficiency of factor VIII or factor IX, respectively. Of the approximately 1 per 5000-10000 male births affected by haemophilia, 80% are deficient in factor VIII and 20% are deficient in factor IX. Haemophilia is...

  • Recombinant Factor VIIa. Dunn, C.J.; Spencer, C.M. // BioDrugs;1999, Vol. 12 Issue 1, p71 

    â–´ Recombinant factor VIIa is a preparation of activated coagulation factor VII (factor VIIa) that is produced by recombinant DNA technology. The drug expedites blood coagulation without the need for factors VIII and IX in patients with haemophilia. â–´ Indicators of activation of...

  • Gene therapy: Genie in a vector. Gould, Julie // Nature;11/27/2014 Supplement, Vol. 515 Issue s7528, pS160 

    The article discusses challenges faced by researchers trying to repair faulty genes causing haemophilia especially in children. Treatments include the infusion of a functional factor IX gene along with DNA to control clotting factor, and a form of gene therapy called genome editing. Research by...

  • haemophilia. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p356 

    An encyclopedia entry for the term "haemophilia" is presented. Haemophilia is a genetic bleeding disease caused by a deficiency of factor VIII blood protein. This condition is sometimes caused by defective genes. Symptoms include recurrent bleeding in the joints and deformity of the knees and...

  • Therapy-resistant haemarthros in a patient with factor VIII inhibitor: successful treatment with recombinant factor VIIa. Lenz, E.; Repas-Humpe, M.; Oldenburg, J.; Kreuz, W.; Schröter, W.; Eber, S. W. // European Journal of Pediatrics;1999, Vol. 158 Issue 11, p951 

    Discusses the treatment of therapy-resistant haemarthos in a patient with factor VIII inhibitor through the use of recombinant factor VIIa. Administration of activated prothrombin complex; Information on bleeding episodes in haemophilia A patients with high titre inhibitor; Inhibitor titre under...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics